Loading...
•
Mar 31, 2023
Supernus Q1 2023 Earnings Report
Reported strong revenue and earnings performance despite generic entry of Trokendi XR.
Key Takeaways
Supernus Pharmaceuticals reported first quarter 2023 total revenues of $153.8 million, a slight increase compared to $152.5 million in the first quarter of 2022. Excluding Trokendi XR, net product sales increased by 25%. The company's GAAP operating earnings were $5.2 million, and non-GAAP operating earnings were $30.5 million. The company raised its full year 2023 GAAP and non-GAAP operating earnings guidance.
Total revenues reached $153.8 million, compared to $152.5 million in Q1 2022.
Qelbree net product sales were $25.8 million, a significant increase from $8.3 million in Q1 2022.
GOCOVRI net product sales increased to $26.0 million, compared to $22.6 million in Q1 2022.
GAAP operating earnings were $5.2 million, up from $2.0 million in Q1 2022.
Revenue by Segment
Forward Guidance
Supernus is increasing its prior financial guidance for GAAP operating loss and non-GAAP operating earnings, lowering financial guidance for combined R&D and SG&A expenses, and maintaining its financial guidance for total revenues for the full year 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...